Novel Peptide Drug Conjugate to Target Recurrent Glioma, a Cancer
with High Unmet Medical Need
“We are excited to advance ANG1005 into further clinical development for primary brain cancer,” said
This Phase 2 clinical study is designed to evaluate the anti-tumor activity of ANG1005 in up to 83 patients with recurrent high-grade glioma at approximately 10 U.S. clinical sites. Study endpoints include objective response rate, progression-free survival and median overall survival, in addition to safety and tolerability. For more information about the study please refer to www.clinicaltrials.gov.
ANG1005 is a novel paclitaxel-peptide drug conjugate that represents the first oncology product to leverage the low density lipoprotein receptor-related protein 1 (LRP-1) pathway to cross the blood-brain barrier (BBB) and enter cancer cells. ANG1005 has been studied in over 200 patients in three clinical studies; two phase 1 studies where the product has shown tolerability similar to paclitaxel and indications of activity, and a Phase 2 study for which the intent-to-treat (ITT) analysis demonstrated encouraging signs of anti-tumor activity and was reported at the 2013
Angiochem is a clinical-stage biotechnology company discovering and developing new breakthrough peptide drug conjugates that leverage the LRP-1 mediated pathway to cross the BBB to treat neurological diseases. These new compounds have the potential to address significant medical needs, many of which are insurmountable due to the fundamental physiological challenge posed by the BBB.
Angiochem is developing a focused product pipeline, including small molecules and biologics, for the potential treatment of a wide range of CNS diseases, including primary brain cancer, brain metastases, lysosomal storage diseases and pain. Founded in 2003, Angiochem maintains headquarters in
The Yates Network